Home LiteratureArticle Details
PMID: 23561594 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Combining cancer immunotherapy and targeted therapy.

Current opinion in immunology ·Vol. 25 ·No. 2 ·2013-04-00 ·Pages 291-6

Ribas A, Wolchok JD

Abstract

The ability to pharmacologically modulate key signaling pathways that drive tumor growth and progression, but do not negatively impact the function of lymphocytes, provides avenues for rational combinatorial approaches to improve the antitumor activity of tumor immunotherapies. Novel targeted agents can very specifically block oncogenic events in cancer cells, leading to a pro-apoptotic milieu and a potential increase in sensitivity to recognition and attack by cytotoxic T lymphocytes (CTLs). Furthermore, targeted pathway modulation in lymphocytes may change their function and have activating effects in some instances. When tested together with recently developed powerful tumor immunotherapies, such combinations may exploit the highly specific targeting of oncogenes with small molecule inhibitors to lead to high frequency of tumor regressions, and merge this benefit with the durable responses achievable with effective tumor immunotherapies.

MeSH Terms
Humans Immunotherapy Molecular Targeted Therapy Neoplasms/immunology,pathology,therapy T-Lymphocytes/immunology
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Ribas Antoni
Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, CA, United States. [email protected]
Wolchok Jedd D
References (51)
51 references, click to expand
  1. Rapamycin: A rheostat for CD8(+) T-cell-mediated tumor therapy.
    Oncoimmunology. 2012 Oct 1;1(7):1189-1190 PMID: 23170275
  2. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.
    Nat Med. 2011 Aug 28;17(9):1094-100 PMID: 21873989
  3. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway.
    Nat Med. 2005 Jan;11(1):71-6 PMID: 15619634
  4. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells.
    Pigment Cell Melanoma Res. 2010 Apr;23(2):190-200 PMID: 20149136
  5. Effects of histone deacetylase inhibitor SAHA on effector and FOXP3+regulatory T cells in rhesus macaques.
    Transplant Proc. 2008 Mar;40(2):459-61 PMID: 18374101
  6. Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors.
    Cancer Res. 2008 Dec 1;68(23):9601-7 PMID: 19047136
  7. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.
    Clin Cancer Res. 2013 Jan 15;19(2):393-403 PMID: 23204132
  8. A novel dendritic cell subset involved in tumor immunosurveillance.
    Nat Med. 2006 Feb;12(2):214-9 PMID: 16444265
  9. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.
    Clin Cancer Res. 2013 Mar 1;19(5):1225-31 PMID: 23307859
  10. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy.
    Cancer Res. 2012 Aug 15;72(16):3928-37 PMID: 22693252
  11. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
    Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4538-46 PMID: 17671140
  12. Progression of RAS-mutant leukemia during RAF inhibitor treatment.
    N Engl J Med. 2012 Dec 13;367(24):2316-21 PMID: 23134356
  13. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B.
    Cancer Res. 2005 Dec 1;65(23):11136-45 PMID: 16322264
  14. Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors.
    J Immunol. 2000 Dec 15;165(12):7017-24 PMID: 11120829
  15. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.
    Clin Cancer Res. 2012 Mar 1;18(5):1386-94 PMID: 22156613
  16. mTOR regulates memory CD8 T-cell differentiation.
    Nature. 2009 Jul 2;460(7251):108-12 PMID: 19543266
  17. Deacetylase inhibition promotes the generation and function of regulatory T cells.
    Nat Med. 2007 Nov;13(11):1299-307 PMID: 17922010
  18. A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity.
    Immunity. 2011 Apr 22;34(4):541-53 PMID: 21511183
  19. Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies.
    Proc Natl Acad Sci U S A. 2011 Mar 8;108(10):4141-6 PMID: 21368108
  20. The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma.
    Int J Cancer. 2008 Jun 1;122(11):2542-53 PMID: 18240144
  21. Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid.
    J Immunol. 2004 Sep 15;173(6):4171-8 PMID: 15356168
  22. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors.
    Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):673-8 PMID: 15637150
  23. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?
    Cancer Cell. 2003 Jul;4(1):13-8 PMID: 12892709
  24. Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824.
    Cancer Res. 2009 Nov 15;69(22):8693-9 PMID: 19861533
  25. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function.
    Blood. 2007 Feb 1;109(3):1123-30 PMID: 17008546
  26. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.
    Cancer Res. 2010 Jul 1;70(13):5213-9 PMID: 20551059
  27. The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin.
    Immunity. 2010 Jan 29;32(1):67-78 PMID: 20060330
  28. Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics.
    Mol Cancer Ther. 2008 Apr;7(4):740-8 PMID: 18413789
  29. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells.
    Mol Cancer Ther. 2004 Apr;3(4):425-35 PMID: 15078986
  30. Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells.
    Blood. 2000 Dec 1;96(12):3847-56 PMID: 11090069
  31. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
    Nature. 2010 Mar 18;464(7287):427-30 PMID: 20179705
  32. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.
    Cell. 2010 Jan 22;140(2):209-21 PMID: 20141835
  33. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.
    J Clin Oncol. 2012 Jan 20;30(3):316-21 PMID: 22067401
  34. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells.
    Nat Med. 2005 Jan;11(1):77-84 PMID: 15619633
  35. Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors.
    Cancer Res. 2012 Feb 1;72(3):581-91 PMID: 22158905
  36. The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations.
    Clin Cancer Res. 2010 Dec 15;16(24):6040-8 PMID: 21169256
  37. BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency.
    Clin Cancer Res. 2012 Apr 15;18(8):2326-35 PMID: 22355009
  38. Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma.
    J Invest Dermatol. 2008 Jun;128(6):1506-16 PMID: 18185535
  39. The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis.
    Biochem Pharmacol. 2003 Oct 15;66(8):1537-45 PMID: 14555232
  40. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma.
    Nat Med. 2007 Jan;13(1):84-8 PMID: 17159987
  41. Targeted therapies to improve tumor immunotherapy.
    Clin Cancer Res. 2008 Jul 15;14(14):4385-91 PMID: 18628452
  42. Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma.
    Oncoimmunology. 2012 Aug 1;1(5):609-617 PMID: 22934253
  43. Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway.
    J Transl Med. 2011 Nov 07;9:192 PMID: 22060015
  44. Methylation of DNA in cancer.
    Adv Clin Chem. 2010;52:145-67 PMID: 21275343
  45. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects.
    J Clin Invest. 2004 Aug;114(3):379-88 PMID: 15286804
  46. Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells.
    Cancer Immunol Immunother. 2008 May;57(5):647-54 PMID: 18046553
  47. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
    Cancer Res. 2005 Jul 15;65(14):6321-9 PMID: 16024634
  48. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
    N Engl J Med. 2012 Jan 19;366(3):207-15 PMID: 22256804
  49. BRAF targeted therapy changes the treatment paradigm in melanoma.
    Nat Rev Clin Oncol. 2011 May 24;8(7):426-33 PMID: 21606968
  50. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors.
    Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3697-702 PMID: 15738394
  51. Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40.
    Blood. 2012 Nov 29;120(23):4533-43 PMID: 22936666
Article Info
Journal
Current opinion in immunology
Abbr.
Curr Opin Immunol
ISSN
1879-0372
DOI
10.1016/j.coi.2013.02.011
Email
[email protected]
Published
2013-04-00
Epub
2013-00-02
Pages
291-6
Language
English
Region
England
NLM ID
8900118
PMCID
PMC3672064
Subset
IM
Grants
NCI NIH HHS · P01 CA132681 · United States
NCI NIH HHS · RC2 CA148468 · United States
NCI NIH HHS · U54 CA119347 · United States
NCI NIH HHS · P50 CA086306 · United States
NCI NIH HHS · R01 CA170689 · United States
NCI NIH HHS · R01 CA056821 · United States
External Links
PubMed source DOI: 10.1016/j.coi.2013.02.011 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2